Genzyme CorporateResearchSearchGenzyme Websites
Patients and FamiliesHeath Care Professionals

Renagel® (sevelamer hydrochloride)

Renagel controls serum phosphorus levels without the concern of calcium or metal accumulation.

New KDOQI guidelines recommend Sevelamer as a first-line option for the reduction of phosphorus in Chronic Kidney Disease (CKD) patients on hemodialysis.1

Patients & Families Health Care Professionals



Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

  • Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.
  • Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation.
  • Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.
  • Patients should be informed to take Renagel with meals and to adhere to their prescribed diets.
  • Please see accompanying full Prescribing Information.
Search

Learn about Renassist, Genzyme’s reimbursement support team.
Go to the Renassist Website >

Global Availability
This website is intended for use in the United States. Renagel is also available in these countries:
Contact Information
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600
Email
Terms and Conditions of Use | Privacy Policy |  This site is intended for United States residents only. RG1061v2
© 2012 Genzyme Corporation. All rights reserved. Renagel and Genzyme are registered trademarks of Genzyme Corporation